Medindia

X

Reportlinker Adds Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer

Thursday, May 26, 2011 General News J E 4
Advertisement

NEW YORK, May 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer

http://www.reportlinker.com/p0284714/Triple-Analysis-Lymphoma-Pancreatic-Cancer-and-Prostate-Cancer.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This triple analysis focuses on cancer drug development strategies in Lymphoma, Pancreatic Cancer and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma

The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Pancreatic Cancer

The pancreatic cancer report part comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.

This part is based on the following publication:

Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?

Part III: Prostate Cancer

The prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma

5.1 The Scope of this Report 26

6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387

7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596

8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636

9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938

11 Disclaimer 939

12 Drug Index 940

13 Company Index 948

Figures: Includes 6 Figures

Tables: Includes 222 Tables

Total Number of Pages: 954

Part II: Pancreatic Cancer

5.1 The Scope of this Report 24

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (171 Drug Targets) 28

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Pancreatic Cancer Therapeutic Pipeline? (142 Drug Target Strategies and 213 Drugs) 333

8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 374

9 Pipeline and Portfolio Planning: Competitive Benchmarking of Pancreatic Cancer Therapeutic Pipeline by Investigator (137 Investigators) 408-599

11 Drug Index 601

12 Company Index 606

Figures: Includes 5 Figures

Tables: Includes 193 Tables

Total Number of Pages: 610

Part III: Prostate Cancer

5.1 The Scope of this Report 28

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (202 Drug Targets) 32-383

7 Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage of Development in the Prostate Cancer Pipeline (187 Drug Target Strategies and 346 Drugs) 384-438

8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 439-485

9 Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate Cancer Therapeutic Pipeline by Investigator (198 Investigators) 486-820

11 Drug Index 822

12 Company Index 831

Figures: Includes 6 Figures

Tables: Includes 257 Tables

Total Number of Pages: 838

To order this report:

Pathology Industry: Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Triple Analysis: Lymphoma, Prost...
S
Reportlinker Adds Triple Analysis: Lymphoma, Prost...